C-SCAPE: Efficacy and safety of 12 weeks of grazoprevir +/-elbasvir +/-ribavirin in patients with HCV GT2, 4, 5 or 6 infection

Authors
Category Primary study
JournalJournal of Hepatology
Year 2015
This article has no abstract
Epistemonikos ID: 70d2692ee81c4d661dea662a9751b9171b102862
First added on: Feb 07, 2025